Active 0 6 0 6 O
, 6 7 6 7 O
known 8 13 8 13 O
or 14 16 14 16 O
suspected 17 26 17 26 O
autoimmune 27 37 27 37 B-chronic_disease
disease 38 45 38 45 I-chronic_disease

Agreement 0 9 46 55 B-contraception_consent
to 10 12 56 58 I-contraception_consent
use 13 16 59 62 I-contraception_consent
effective 17 26 63 72 I-contraception_consent
methods 27 34 73 80 I-contraception_consent
of 35 37 81 83 I-contraception_consent
contraception 38 51 84 97 I-contraception_consent
per 52 55 98 101 O
the 56 59 102 105 O
protocol 60 68 106 114 O
requirements 69 81 115 127 O

ECOG 0 4 128 132 B-clinical_variable
performance 5 16 133 144 I-clinical_variable
status 17 23 145 151 I-clinical_variable
of 24 26 152 154 O
0 27 28 155 156 B-lower_bound
or 29 31 157 159 O
1 32 33 160 161 B-upper_bound

Histologically 0 14 162 176 O
or 15 17 177 179 O
cytologically 18 31 180 193 O
confirmed 32 41 194 203 O
, 41 42 203 204 O
immunotherapy 43 56 205 218 B-treatment
na√Øve 57 62 219 224 I-treatment
or 63 65 225 227 O
PD-1 66 70 228 232 B-treatment
/ 70 71 232 233 I-treatment
PD 71 73 233 235 I-treatment
- 73 74 235 236 I-treatment
L1 74 76 236 238 I-treatment
pre 77 80 239 242 O
- 80 81 242 243 O
treated 81 88 243 250 O
, 88 89 250 251 O
metastatic 90 100 252 262 B-cancer
or 101 103 263 265 O
locally 104 111 266 273 O
advanced 112 120 274 282 O
non 121 124 283 286 B-cancer
- 124 125 286 287 I-cancer
small 125 130 287 292 I-cancer
cell 131 135 293 297 I-cancer
lung 136 140 298 302 I-cancer
cancer 141 147 303 309 I-cancer
not 148 151 310 313 O
amenable 152 160 314 322 O
to 161 163 323 325 O
curative 164 172 326 334 O
treatment 173 182 335 344 B-treatment

History 0 7 345 352 O
of 8 10 353 355 O
( 11 12 356 357 O
non 12 15 357 360 O
- 15 16 360 361 O
infectious 16 26 361 371 O
) 26 27 371 372 O
pneumonitis 28 39 373 384 B-chronic_disease
that 40 44 385 389 O
required 45 53 390 398 O
corticosteroids 54 69 399 414 B-treatment
or 70 72 415 417 O
current 73 80 418 425 O
pneumonitis 81 92 426 437 O

History 0 7 438 445 O
of 8 10 446 448 O
life 11 15 449 453 O
- 15 16 453 454 O
threatening 16 27 454 465 O
toxicity 28 36 466 474 O
related 37 44 475 482 O
to 45 47 483 485 O
prior 48 53 486 491 O
anti 54 58 492 496 B-treatment
- 58 59 496 497 I-treatment
PD-1 59 63 497 501 I-treatment
/ 63 64 501 502 I-treatment
PD 64 66 502 504 I-treatment
- 66 67 504 505 I-treatment
L1 67 69 505 507 I-treatment
treatment 70 79 508 517 I-treatment
for 80 83 518 521 O
subjects 84 92 522 530 O
with 93 97 531 535 O
metastatic 98 108 536 546 B-cancer
melanoma 109 117 547 555 I-cancer
or 118 120 556 558 O
NSCLC 121 126 559 564 B-cancer

Negative 0 8 565 573 B-pregnancy
pregnancy 9 18 574 583 I-pregnancy
test 19 23 584 588 O
for 24 27 589 592 O
women 28 33 593 598 B-gender
of 34 36 599 601 O
child 37 42 602 607 O
bearing 43 50 608 615 O
potential 51 60 616 625 O

Second 0 6 626 632 B-cancer
malignancy 7 17 633 643 I-cancer
( 18 19 644 645 O
solid 19 24 645 650 B-cancer
or 25 27 651 653 O
hematologic 28 39 654 665 B-cancer
) 39 40 665 666 O
within 41 47 667 673 O
the 48 51 674 677 O
past 52 56 678 682 B-upper_bound
3 57 58 683 684 I-upper_bound
years 59 64 685 690 I-upper_bound
except 65 71 691 697 O
locally 72 79 698 705 O
curable 80 87 706 713 B-cancer
cancers 88 95 714 721 I-cancer
that 96 100 722 726 O
have 101 105 727 731 O
been 106 110 732 736 O
apparently 111 121 737 747 O
cured 122 127 748 753 O

Subjects 0 8 754 762 O
may 9 12 763 766 O
be 13 15 767 769 O
treatment 16 25 770 779 B-treatment
naive 26 31 780 785 O
or 32 34 786 788 O
could 35 40 789 794 O
have 41 45 795 799 O
received 46 54 800 808 O
one 55 58 809 812 O
prior 59 64 813 818 O
platinum 65 73 819 827 B-treatment
based 74 79 828 833 I-treatment
chemotherapy 80 92 834 846 I-treatment
for 93 96 847 850 O
non 97 100 851 854 B-cancer
- 100 101 854 855 I-cancer
small 101 106 855 860 I-cancer
cell 107 111 861 865 I-cancer
lung 112 116 866 870 I-cancer
cancer 117 123 871 877 I-cancer
and 124 127 878 881 O
subjects 128 136 882 890 O
with 137 141 891 895 O
a 142 143 896 897 O
documented 144 154 898 908 O
activating 155 165 909 919 O
mutation 166 174 920 928 O
( 175 176 929 930 O
e.g. 176 180 930 934 O
, 180 181 934 935 O
EGFR 182 186 936 940 B-clinical_variable
, 186 187 940 941 O
ALK 188 191 942 945 B-clinical_variable
, 191 192 945 946 O
ROS 193 196 947 950 B-clinical_variable
) 196 197 950 951 O
must 198 202 952 956 O
also 203 207 957 961 O
have 208 212 962 966 O
received 213 221 967 975 O
the 222 225 976 979 O
appropriate 226 237 980 991 O
therapy 238 245 992 999 O
and 246 249 1000 1003 O
progressed 250 260 1004 1014 O

Subjects 0 8 1015 1023 O
with 9 13 1024 1028 O
BRAF 14 18 1029 1033 B-cancer
activating 19 29 1034 1044 I-cancer
mutation 30 38 1045 1053 I-cancer
could 39 44 1054 1059 O
have 45 49 1060 1064 O
also 50 54 1065 1069 O
received 55 63 1070 1078 O
a 64 65 1079 1080 O
BRAF 66 70 1081 1085 B-treatment
inhibitor 71 80 1086 1095 I-treatment
and/or 81 87 1096 1102 O
MEK 88 91 1103 1106 B-treatment
inhibitor 92 101 1107 1116 I-treatment
regimen 102 109 1117 1124 I-treatment
prior 110 115 1125 1130 O
to 116 118 1131 1133 O
anti 119 123 1134 1138 B-treatment
- 123 124 1138 1139 I-treatment
PD-1 124 128 1139 1143 I-treatment
/ 128 129 1143 1144 I-treatment
PD 129 131 1144 1146 I-treatment
- 131 132 1146 1147 I-treatment
L1 132 134 1147 1149 I-treatment
therapy 135 142 1150 1157 I-treatment

